Genetic testing for people with multiple myeloma and chronic lymphocytic leukaemia

This page provides information new and amended MBS items available for the diagnosis of multiple myeloma and chronic lymphocytic leukaemia from 1 November 2021

Page last updated: 17 November 2021

From 1 November 2021, new and amended MBS Items for genome-wide microarray (GWMA) testing will be introduced for the diagnosis of multiple myeloma and chronic lymphocytic leukaemia.

New item 73391 for GWMA testing will be introduced for the diagnosis of multiple myeloma.

Item 73343 with be amended so that individuals with relapsed or refractory chronic lymphocytic leukaemia will be able to access GWMA testing for the detection of 17p chromosomal deletion, in addition to existing fluorescence in-situ hybridisation (FISH) testing, to determine eligibility for treatment with idelalisib, ibrutinib, venetoclax, or acalabrutinib

These changes will improve diagnosis processes and guide appropriate treatment options in people with multiple myeloma and chronic lymphocytic leukaemia.


PDF version Factsheet - Genetic testing for multiple myeloma and chronic lymphocytic leukaemia (PDF 202 KB)
Word version Factsheet - Genetic testing for multiple myeloma and chronic lymphocytic leukaemia (Word 85 KB)


In this section